MCID: AML051
MIFTS: 19

Aml with Myelodysplasia-Related Features

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Aml with Myelodysplasia-Related Features

MalaCards integrated aliases for Aml with Myelodysplasia-Related Features:

Name: Aml with Myelodysplasia-Related Features 52
Acute Myeloid Leukaemia with Myelodysplasia-Related Features 52
Acute Myeloid Leukemia with Multilineage Dysplasia 52
Aml with Multilineage Dysplasia 52

Classifications:



Summaries for Aml with Myelodysplasia-Related Features

MalaCards based summary : Aml with Myelodysplasia-Related Features, also known as acute myeloid leukaemia with myelodysplasia-related features, is related to leukemia, acute myeloid and myeloid leukemia. The drugs Fludarabine and Clotrimazole have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow.

Related Diseases for Aml with Myelodysplasia-Related Features

Diseases related to Aml with Myelodysplasia-Related Features via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 17)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute myeloid 11.7
2 myeloid leukemia 10.7
3 myelodysplastic syndrome 10.5
4 leukemia 10.3
5 autoimmune disease 10.2
6 myeloma, multiple 10.2
7 leukemia, acute lymphoblastic 10.2
8 graft-versus-host disease 10.2
9 membranous nephropathy 10.2
10 lymphoproliferative syndrome 10.2
11 childhood acute myeloid leukemia 10.2
12 neutropenia 10.2
13 pancytopenia 10.2
14 thrombocytopenia 10.2
15 thrombocytosis 10.2
16 glomerulonephritis 10.2
17 47,xyy 10.2

Graphical network of the top 20 diseases related to Aml with Myelodysplasia-Related Features:



Diseases related to Aml with Myelodysplasia-Related Features

Symptoms & Phenotypes for Aml with Myelodysplasia-Related Features

Drugs & Therapeutics for Aml with Myelodysplasia-Related Features

Drugs for Aml with Myelodysplasia-Related Features (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 80)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fludarabine Approved Phase 3 21679-14-1, 75607-67-9 30751
2
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
3
Mycophenolic acid Approved Phase 3 24280-93-1 446541
4
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
5
Tacrolimus Approved, Investigational Phase 3 104987-11-3 445643 439492 6473866
6
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
7
Busulfan Approved, Investigational Phase 3 55-98-1 2478
8
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
9
leucovorin Approved Phase 3 58-05-9 6006 143
10
Azacitidine Approved, Investigational Phase 3 320-67-2 9444
11
Decitabine Approved, Investigational Phase 3 2353-33-5 451668
12
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
13
Daunorubicin Approved Phase 3 20830-81-3 30323
14
Clofarabine Approved, Investigational Phase 3 123318-82-1 119182
15
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
16 Antitubercular Agents Phase 3
17 Antifungal Agents Phase 3
18 Cyclosporins Phase 3
19 Calcineurin Inhibitors Phase 3
20 Dermatologic Agents Phase 3
21 Antirheumatic Agents Phase 3
22 Alkylating Agents Phase 3
23 Vitamin B Complex Phase 3
24 Folate Phase 3
25 Folic Acid Antagonists Phase 3
26 Vitamin B9 Phase 3
27 Antimetabolites Phase 3
28 Immunologic Factors Phase 3
29 Anti-Infective Agents Phase 3
30 Antiviral Agents Phase 3
31 Immunosuppressive Agents Phase 3
32 Anti-Bacterial Agents Phase 3
33 Antibiotics, Antitubercular Phase 3
34
Etoposide Approved Phase 2 33419-42-0 36462
35
Lenograstim Approved, Investigational Phase 2 135968-09-1
36
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
37
Vidarabine Approved, Investigational Phase 2 24356-66-9 21704 32326
38
Mitoxantrone Approved, Investigational Phase 2 65271-80-9 4212
39
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
40
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
41
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
42 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
43
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
44
Melphalan Approved Phase 1, Phase 2 148-82-3 460612 4053
45
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030 46835353
46
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
47
midostaurin Approved, Investigational Phase 2 120685-11-2 104937 9829523
48
Glycine Approved, Nutraceutical, Vet_approved Phase 2 56-40-6 750
49
tipifarnib Investigational Phase 2 192185-72-1 159324
50
Entinostat Investigational Phase 2 209783-80-2

Interventional clinical trials:

(show all 22)
# Name Status NCT ID Phase Drugs
1 A Multi-center Phase III Study Comparing Myeloablative to Nonmyeloablative Transplant Conditioning in Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia Completed NCT00322101 Phase 3 cyclophosphamide;mycophenolate mofetil;busulfan;cyclosporine;fludarabine phosphate;tacrolimus;methotrexate
2 Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years) Active, not recruiting NCT02085408 Phase 3 clofarabine;daunorubicin hydrochloride;cytarabine;decitabine
3 A Randomized Phase II Trial of Tipifarnib (R115777, ZARNESTRA, NSC #702818) in Combination With Oral Etoposide (VP-16) in Elderly Adults With Newly Diagnosed, Previously Untreated Acute Myelogenous Leukemia (AML) Completed NCT00602771 Phase 2 tipifarnib;etoposide
4 Phase 2 Study of Early Discharge and Outpatient Management of Adult Patients Following Intensive Chemotherapy for MDS and Non-APL AML Completed NCT01235572 Phase 2
5 A Phase II Study of Farnesyl Transferase Inhibitor R115777 (Zarnestra) (R115777 ( Zarnestra), Tipifarnib, R115777, NSC #702818) in Elderly Patients With Previously Untreated Poor-Risk Acute Myeloid Leukemia Completed NCT00027872 Phase 2 tipifarnib
6 Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation From HLA Matched Related Donors for Treatment of Older Patients With De Novo or Secondary Acute Myeloid Leukemia in First Complete Remission Completed NCT00045435 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
7 A Randomized Phase II Trial of Azacitidine With or Without the Histone Deacetylase Inhibitor Entinostat for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (Dysplastic Type), and Acute Myeloid Leukemia With Multilineage Dysplasia Completed NCT00313586 Phase 2 Azacitidine;Entinostat
8 A Phase II Study of Tosedostat in Combination With Either Cytarabine or Decitabine in Newly Diagnosed AML or High-Risk MDS Completed NCT01567059 Phase 2 tosedostat;cytarabine;decitabine
9 Decitabine Followed by Bone Marrow Transplant and High-Dose Cyclophosphamide for the Treatment of Relapsed and Refractory Acute Myeloid Neoplasms Completed NCT01707004 Phase 2 decitabine;fludarabine phosphate;busulfan;cyclophosphamide;tacrolimus;mycophenolate mofetil
10 Randomized Phase II Trial of Timed Sequential Therapy (TST) With Alvocidib (Flavopiridol), Ara-C and Mitoxantrone (FLAM) vs. "7+3" for Adults Age 70 and Under With Newly Diagnosed Acute Myelogenous Leukemia (AML) Completed NCT01349972 Phase 2 alvocidib;daunorubicin hydrochloride;mitoxantrone hydrochloride;cytarabine
11 Randomized Phase II Study Comparing Two Administration Schedules of Flavopiridol (Alvocidib, NSC 649890, IND 46, 211) Given in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone Hydrochloride for Adults With Newly Diagnosed, Previously Untreated, Poor Risk Acute Myelogenous Leukemias (AML) Completed NCT00795002 Phase 2 alvocidib;mitoxantrone hydrochloride;cytarabine
12 Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
13 Phase Ib/II Study of the Glutaminase Inhibitor CB-839 in Combination With Azacitidine in Patients With Advanced Myelodysplastic Syndrome Recruiting NCT03047993 Phase 1, Phase 2 Azacitidine;Glutaminase Inhibitor CB-839
14 A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Elderly Patients With Acute Myeloid Leukemia Undergoing Remission Induction Therapy Active, not recruiting NCT02071901 Phase 2 eltrombopag olamine
15 Allogeneic Stem Cell Transplant With a Novel Conditioning Therapy Using Helical Tomotherapy, Melphalan, and Fludarabine in Hematological Malignancies Active, not recruiting NCT00544466 Phase 1, Phase 2 fludarabine phosphate;melphalan
16 A Phase II Study of Subcutaneous Bortezomib as Maintenance Therapy for Patients With High-risk Acute Myeloid Leukemia in Remission Terminated NCT01465386 Phase 2 bortezomib
17 OAG and Decitabine for Newly Diagnosed Acute Myeloid Leukemia Patients Greater Than or Equal to 65 Years of Age Terminated NCT02029417 Phase 2 cytarabine;omacetaxine mepesuccinate;decitabine
18 A Phase 2 Study of Decitabine in Combination With Midostaurin (PKC412) for Elderly Patients With Newly Diagnosed FLT3-ITD/TKD Positive Acute Myeloid Leukemia Terminated NCT01846624 Phase 2 Decitabine;Midostaurin
19 Phase I Trial of R115777 (NSC 702818) in Relapsed, Refractory or High Risk Myeloid Leukemia Completed NCT00101296 Phase 1 tipifarnib
20 A Phase 1 Study of Suberoylanilide Hydroxamic Acid (Vorinostat, SAHA) in Combination With Idarubicin in Relapsed or Refractory Leukemia Completed NCT00331513 Phase 1 vorinostat;idarubicin
21 Characterization of the Mechanisms of Action of Resistance to Azacitidine in High-risk Myelodysplastic Syndromes and Acute Myeloid Leukemia With Multilineage Dysplasia Unknown status NCT01210274
22 Pilot Study of Feasibility, Safety, and Economics of Early Discharge and Outpatient Management of Adult Patients Following Intensive Induction Chemotherapy for Myelodysplastic Syndrome and Non-APL Acute Myeloid Leukemia Completed NCT00844441

Search NIH Clinical Center for Aml with Myelodysplasia-Related Features

Genetic Tests for Aml with Myelodysplasia-Related Features

Anatomical Context for Aml with Myelodysplasia-Related Features

MalaCards organs/tissues related to Aml with Myelodysplasia-Related Features:

40
Myeloid, Bone, Bone Marrow, T Cells

Publications for Aml with Myelodysplasia-Related Features

Articles related to Aml with Myelodysplasia-Related Features:

(show all 29)
# Title Authors PMID Year
1
Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia. 61
26209197 2015
2
Characteristics of Sweet Syndrome in patients with acute myeloid leukemia. 61
25630528 2015
3
Epigenetic therapies in MDS and AML. 61
22956506 2013
4
Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity. 61
22442349 2012
5
Acute Myeloid Leukemia With Myelodysplasia-Related Changes: A New Definition. 61
26839302 2010
6
New classification of acute myeloid leukemia and precursor-related neoplasms: changes and unsolved issues. 61
21034669 2010
7
Recent advances in the diagnosis and classification of myeloid neoplasms--comments on the 2008 WHO classification. 61
20626469 2010
8
A hospital-based case-control study of acute myeloid leukemia in Shanghai: analysis of environmental and occupational risk factors by subtypes of the WHO classification. 61
19900423 2010
9
Disappearing myelodysplastic syndrome-associated hemolytic anemia in leukemic transformation. 61
20197683 2010
10
Duplication of isodicentric chromosome 21, idic(21)(p11.2), leading to pentasomy 21q in acute myeloid leukemia with multilineage dysplasia. 61
19737652 2009
11
[Successful treatment with intensive immunosuppressive therapy and mechanical ventilation for idiopathic pneumonia syndrome following allogeneic bone marrow transplantation]. 61
19638724 2009
12
Syndrome of inappropriate antidiuretic hormone secretion associated with acute myeloid leukemia with multilineage dysplasia. 61
19367383 2009
13
Acute myeloid leukemia with multilineage dysplasia in an alpaca. 61
18761521 2008
14
Diagnosis of acute myeloid leukemia according to the WHO classification in the Japan Adult Leukemia Study Group AML-97 protocol. 61
18256787 2008
15
Bone marrow trephine findings in acute myeloid leukaemia with multilineage dysplasia. 61
17973948 2008
16
Acute myeloid leukemia with multilineage dysplasia in children. 61
18055345 2007
17
Prospective study of 174 de novo acute myelogenous leukemias according to the WHO classification: subtypes, cytogenetic features and FLT3 mutations. 61
16573742 2006
18
Immunoreactivity of MIC2 (CD99) and terminal deoxynucleotidyl transferase in bone marrow clot and core specimens of acute myeloid leukemias and myelodysplastic syndromes. 61
16454553 2006
19
Classification of myeloid neoplasms: a comparative review. 61
16134066 2005
20
Long-term outcomes for unselected patients with acute myeloid leukemia categorized according to the World Health Organization classification: a single-center experience. 61
15813916 2005
21
Dominant and opportunistic leukemic clones: proposal for a pathogenesis-oriented classification in acute myeloid leukemia. 61
15893127 2005
22
DNA microarray analysis of dysplastic morphology associated with acute myeloid leukemia. 61
15345284 2004
23
Pathogenic pathways in acute myeloid leukemias. 61
15984661 2004
24
Plasma soluble interleukin-2 receptor (sIL-2R) levels in patients with acute leukemia. 61
15648782 2004
25
[Intensive multi-drug chemotherapy for acute myeloid leukemia in a renal allograft recipient]. 61
14639948 2003
26
Detection of NPM/MLF1 fusion in t(3;5)-positive acute myeloid leukemia and myelodysplasia. 61
14506644 2003
27
Acute myeloid leukemia in elderly patients: experience of a single center. 61
12792698 2003
28
Efficacy and toxicity of low-dose melphalan in myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia. 61
12937849 2003
29
Acute myeloid leukaemia M0: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients. 61
11380465 2001

Variations for Aml with Myelodysplasia-Related Features

Expression for Aml with Myelodysplasia-Related Features

Search GEO for disease gene expression data for Aml with Myelodysplasia-Related Features.

Pathways for Aml with Myelodysplasia-Related Features

GO Terms for Aml with Myelodysplasia-Related Features

Sources for Aml with Myelodysplasia-Related Features

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....